HomeAI · summaries
Storia in 4 fonti
Ibrance nabs FDA approval for HR-positive, HER2-positive metastatic breast cancer
The FDA has approved the first and only cyclin-dependent kinase 4/6 inhibitor for patients with HR-positive metastatic breast cancer, regardless of HER2 status. Palbociclib (Ibrance, Pfizer) was approved in combination with trastuzumab (Herceptin, Genentech), with or without pertuzumab (Perjeta, Genetech), and endocrine therapy as maintenance treatment for adults with HR-positive,
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Ibrance nabs FDA approval for HR-positive, HER2-positive metastatic breast cancer
The FDA has approved the first and only cyclin-dependent kinase 4/6 inhibitor for patients with HR-positive metastatic breast cancer, regardless of HER2 status. Palbociclib…
- ·
medpagetoday.com
FDA Approves CDK4/6 Inhibitor for HER2-Positive Breast Cancer
PATINA trial paved the way for palbociclib-based frontline maintenance regimen
